ARTICLE | Company News

Santarus, Otsuka sales and marketing update

October 11, 2004 7:00 AM UTC

SNTS launched in the U.S. its Zegerid powder 20 mg, an immediate-release oral suspension of the proton pump inhibitor omeprazole, to treat heartburn and other symptoms related to gastroesophageal reflux disease (GERD), to treat and maintain healing of erosive esophagitis and to treat duodenal ulcers. The company said it has a sales force of more than 200 people. An NDA for a 40 mg formulation of Zegerid is under FDA review to treat gastric ulcers and to prevent upper GI bleeding in critically ill patients and has a Dec. 26 PDUFA date. ...